HIGHLIGHTS
- who: Huilai Lv from the Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Department of have published the research work: Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma, in the Journal: (JOURNAL) of December/31,/2021
- what: This study demonstrated that patients diagnosed at earlier stages or completed 3-4 cycles of neoadjuvant treatment had a better pCR rate. Taken together, the study provided the essential clinical insights into real-world neoadjuvant chemo-immunotherapy for resectable locally advanced ESCC.
SUMMARY
In light . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.